Skip Ribbon Commands
Skip to main content

Summary Slides

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   Reference Center   |   Slides and Reports   |   Summary Slides
  • Print
  • Share

The US Summary Slides - HCT Trends and Survival Data

Using information from our outcomes database, CIBMTR annually prepares and distributes charts summarizing current uses and outcomes of allogeneic and autologous hematopoietic cell transplantation (HCT) in a set of US Summary Slides.

The US Summary Slides

The US Summary Slides are an annual report on data submitted to the CIBMTR by centers in the US and describes information related to practices and general survival outcomes after hematopoietic cell transplantation. The current edition includes transplants performed prior to 2021.

The US Summary Slides 2021 (PowerPoint)

(Select "Open in PowerPoint" option to view presentation)

  • Slides 2 to 73 exhibit data on frequency of transplants according to transplant type, donor, patient age, graft source, GVHD prophylaxis, disease, causes of death, conditioning regimen, and race and/or ethnicity. All frequencies represent first autologous and allogeneic transplants registered with the CIBMTR during the period. 

  • Slides 74 to 117 include overall survival outcomes according to age, donor type, disease, disease status, year of transplant, and race and ethnicity. Comparisons across survival curves are univariate and do not adjust for all potentially important factors; consequently, results should be interpreted cautiously.

The US Summary Slides 2021: COVID-19 Related (PowerPoint)

(Select "Open in PowerPoint" option to view presentation)

  • This year the CIBMTR is also providing a set of slides showing various aspects of data reported to CIBMTR related to COVID-19 infections in patients between January 1, 2020, and October 31, 2021.

Return to top

To cite the US Summary Slides

Auletta J.J., Kou J., Chen M., Shaw B.E. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2021.

Return to top

Request the US Summary Slides

Slides are also available upon request by contacting

Return to top

Supplemental information on the US Summary Slides

  • Acute myelogenous leukemia (AML), and acute lymphocytic leukemia (ALL) have disease status at HCT classified as CR1, CR2+ (2nd or subsequent complete remission) and relapse/ never in CR (includes primary induction failure).

  • Myelodysplastic syndromes (MDS) stage is divided into:

    • Low risk (refractory anemia [RA] or refractory anemia with ringed sideroblasts [RARS], refractory cytopenia with unilineage dysplasia [RCUD], refractory cytopenia with multilineage dysplasia [RCMD], MDS with isolated del(5q)).

    • High risk (refractory anemia with excess blasts [RAEB] or chronic myelomonocytic leukemia [CMML]) disease).

  • Myeloproliferative neoplasms (MPN) include myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myelomonocytic leukemia, chronic myeloproliferative disease-unclassifiable, chronic neutrophilic leukemia, chronic eosinophilic leukemia and MPN-not otherwise specified.

  • Chronic myelogenous leukemia (CML) have disease stage classified as hematologic CR, chronic phase, accelerated phase or blast crisis

  • Lymphoma is classified according to sensitivity to prior chemotherapy (chemosensitive or chemoresistant).

  • The classification of conditioning regimen intensity is based on the agents, doses and schedules used. Several classification systems are available, and for this report we used a composite classification. Cases defined as reduced-intensity by the transplant center were classified as such. Cases without such information and with available data on chemotherapy agents, radiation and doses, were classified according to the CIBMTR operational definition of conditioning regimen intensity:

    • Myeloablative conditioning: Regimens with total body irradiation doses of ≥500 cGY, single fractionated doses of ≥800 cGY, busulfan doses of >9mg/kg oral or Bu >= 7.2 mg/kg IV, or melphalan doses of >150 mg/m2 given as single agents or in combination with other drugs.

    • Reduced-intensity conditioning/Non-myeloablative regimen: Regimens with lower doses of total body irradiation, fractionated radiation therapy, busulfan, and melphalan than those used to define a myeloablative conditioning regimen (above).

Return to top


View current and planned studies
Last Updated: 5/20/2022 1:24 PM